Look at Gets Global and HWGB. Do you think they are excellent companies. With red QRs, but the price can up much.

The cause is the power of demand for their shares give them momentum to be shoot up tremendously.

I hope you, char1234 can answer this question honestly.....

@char1234. Even the dead company can be transformed it to be alive. Nexgram never died, it just have many problems in the past few years. Think about it wisely Dear Friend.

To recap:

@OKU_2020. mmm...
Your know the Probability theory ?...MATH
--------------------------------

Tiada yang mustahil dalam saham. Kalau ikut teori probability, kemungkinannya sebelum ini sepatutnya RENDAH, tetapi yang berlaku sebaliknya.

1. GETS GLOBAL BERHAD dari 4.5 sen pada 23 Mac 2020 boleh mencecah setinggi RM3.97.
2. Lebih dekat lagi dengan Nexgram (already been a vaccine counter) ialah saham HWGB (sebab covid-19 vaksin) dari harga terendah 6 sen mencapai harga tertinggi RM1.03.

Note: Betullah kedua-duanya saham spekulatif....

Dari bilik sebelah:
-----------------------------------------
paktua73, [12.12.20 10:16]
morning all nxgram warriors..
after paktua study the rally pattern for nxgram..
this paktua own personal view..

nexgram will start rally on jan after all vaccines start hot

paktua will start fight here on mid jan

paktua73, [12.12.20 10:18]
paktua aimed rm 0.50 on april (personal target yer

@Singapore88. Good. But I never clearly stated my TP except more than 12 sen and above. Then I want to recap this.. He He
--------------------------
MZM2511 rumours..... By the way, sifu paktua73 tut tut just predicted Nexgram's price can go to @50 sen on April 2021. He He

OKU_2020. When the theory of demand fully in place, Ozura will be the history in Nexgram

Good. Mr Botak. Tengok. Si OKU_2020 sudah kepanasan.

I will stick to my plans. Have to believe it. It's good for contrarrian.
They come to nexgram counter, and its also gives me a pleasure. As a sign there will be a future days where so many investors will come and punter the stocks, more demand for it, BOOOOOOOM. Its my day to become half millionaire or at the best a millionaire. Insha Allah

Brother ,,u have write up on bornoil,,like to buys ,can invest
-----------------------------------
If want to invest please buy it as you think it is at its lower. Just my idea only

https://www.thestar.com.my/business/business-news/2020/12/12/the-business-of-covid-vaccines

@OKU_2020. mmm...
Your know the Probability theory ?...MATH
--------------------------------

Tiada yang mustahil dalam saham. Kalau ikut teori probability, kemungkinannya sebelum ini sepatutnya RENDAH, tetapi yang berlaku sebaliknya.

1. GETS GLOBAL BERHAD dari 4.5 sen pada 23 Mac 2020 boleh mencecah setinggi RM3.97.
2. Lebih dekat lagi dengan Nexgram (already been a vaccine counter) ialah saham HWGB (sebab covid-19 vaksin) dari harga terendah 6 sen mencapai harga tertinggi RM1.03.

Note: Betullah kedua-duanya saham spekulatif....

rumours..... By the way, sifu paktua73 tut tut just predicted Nexgram's price can go to @50 sen on April 2021. He He

@OKU_2020. mmm...
Your know the Probability theory ?...MATH
--------------------------------

Won't use probabilty theory.
I'm trained in accounting and economics. Will use those theories. The past for Nexgram was over.

Emerge developments in the current and future businesses-- Show better financial conditions + Good rumours on the company --- Attract more investor -- The demand for the company shares exceeds supply ... THE PRICE OF THE COMPANY SHARES WILL APPRECIATE

THAT'S TRUE ESSENCE OF THE ACCOUNTING AND ECONOMICS THEORY

Now already news...no more excitement...that's why this Cap Ayam Nexgram is losing steam & Kaput-ing now ...
-----------------------------------------------------

I will wait for the news which will show the progress of the JV. Any good news, NEXGRAM KABOOOOOOOOOOOOOOM. What say you?

Please just offer us the facts or your true logic, not a naysayer ideas only.. He He He

OKU_2020. I'm a long term investors (actually caused being trapped long time before but won't accept to cut loss or break even).
Now I'm preparing to win big in this counter. He He He He He

THOSE RULE WON'T SUITS ME AND OTHER MEDIUM AND LONG TERM INVESTORS

4. Rafarma Pharmaceuticals, Inc. OTC:(RAFA) reported that one of the acquisition companies of the previously-announced Biocogency merger, Bebig LLC received an updated Russian registration certificate for the production and sale of nanostructured microspheres based on yttrium-90, used in the treatment of both primary and metastatic liver lesions.

CONCLUSION:…

The JV are not announcing any covid-19 vaccine yet. But based on my study, Rafarma has a subsidiary Kraspharma in Russia, which has a probabilty to cater vaccine from Russia— Sputnik V vaccine.

All are the relationship between Rafarma and the Russian Goverment. Linking: Rafarma in USA - Krasfarma in Russia -- Vaccinelab -- Russian Covid-19 vaccine candidate - Indonesia and the Asean countries.

And it also has a possibility to cater other Covid-19 vaccine candidates, including from China.

THE REASONS:….
1. Based on BURSA announcement:
VACCINESLAB and RAFARMA desire to jointly develop and conduct initial clinical trial and expanded clinical trial (“Clinical Trial”) and invest in LARGE-SCALE COVID-19 VACCINE FACILITY IN INDONESIA (“Vaccine Plant”) exclusively for the above and other various vaccines as well as other immunological promising drug, use developed by RAFARMA, especially clinical trials in regional trial sites outside of USA and China with this MSJVA.

2. THIS ONE I THINK IMPORTANT: ....... Penny Lukito, the head of Indonesia’s food and drugs agency, BPOM, told reporters on Thursday that the agency had also been approached by American pharmaceutical giant Pfizer and British firm AstraZeneca, as well as by THE DEVELOPER OF RUSSIA'S SPUTNIK V vaccines “to talk about the possibility of launching clinical trials for their Covid-19 vaccines in Indonesia”. ...... The Russian government had sent a letter to the Indonesia’s Health Ministry in September over the possibility of Sputnik V vaccine distribution, procurement and clinical trials. Preliminary results on the vaccine, which is currently in phase-three clinical trials, show its efficacy rate at 92 per cent, according to its developer, Gamaleya Research Institute.

3. ---- Indonesia said Thursday that it had been approached by several drug makers whose Covid-19 vaccine candidates have shown promising early results to either test or produce their vaccines, moving the country a step closer to becoming Southeast Asia’s vaccine production and distribution hub.

TITLE:.. A THEORY ABOUT A JOINT VENTURE BETWEEN VACCINE LAB (s/o NEXGRAM) WITH RAFARMA (US company)

(To open a vaccine facility in Indonesia to research, develop, conduct clinical trials and license for various in-demand vaccines including Covid-19)

RESEARCH QUESTION:

Which Covid-19 Vaccine candidates is going to be secured by the JV ?

HYPOTHESIS:

Based on the JV, there is a probability on the JV to cater any Covid-19 Vaccine candidate which can be conducted clinical trials and license for produced in Indonesia, and distributed by the JV to Indonesia and the other ASEAN countries.

THE JV:

R. & D. Biocogency Laboratories Inc (Cyprus)
(parent company of RAFARMA)
I
RAFARMA (US) ------------------------------- JV Vaccines Lab I
PJSC Kraspharma(sub of RAFARMA) (Russia)

THEN:……..

A BIG BIG POSSIBILITY:

Vaccine Lab + Rafarma Pharmaceuticals (US) + R. & D. Biocogency Laboratories Inc. (Cyprus) + subsidiary of Rafarma, PJSC Kraspharma (Russia) ———-> Russian or other source country Covid-19 vaccine ———> Indonesia and the ASEAN countries

Selamat pagi

The 13 Covid-19 vaccines in the final stages of testing to be used in Malaysia
Category: Inactivated virus vaccines
1. Sinovac
2. Wuhan Institute of Biological Products / Sinopharm,
3. Beijing Institute of Biological Products / Sinopharm
4. Bharat Biotech
Category: Non-replicating viral vector vaccines
5. University of Oxford / AstraZeneca
6. CanSino Biological Inc / Beijing Institute of Biotechnology
7. Gamaleya Research Institute
Russia’s Gamaleya National Center of Epidemiology and Microbiology said the Sputnik V vaccine candidate it developed involves what it described as a unique method of using two different types of adenovirus vectors (rAd26 and rAd5) for the first and second doses of vaccination with the aim of producing a stronger and longer-term immune response. The doses are said to be given 21 days apart. Gamaleya Center claims Sputnik V to have an efficacy rate of more than 90 per cent.
On November 24, Russia’s sovereign wealth fund Russian Direct Investment Fund (RDIF) said the cost of Sputnik V in international markets will be less than US$20 for two doses, while the freeze-dried form of the vaccine candidate is said to be able to be stored at a temperature of between 2 to 8 degrees Celsius.
According to the Gamaleya Center and RDIF, a Phase III trial in Russia involving 40,000 volunteers is underway, and Phase III trials are also ongoing in other countries such as Belarus, the UAE and Venezuela, while a Phase II-III trial is being undertaken in India.
8. Janssen Pharmaceutical Companies
Category: Protein-based vaccines
9. Novavax
10. Anhui Zhifei Longcom Biopharmaceutical / Institute of Microbiology, Chinese Academy of Sciences
Category: RNA / DNA vaccines
11. Moderna / NIAID
12. Pfizer / BioNTech / Fosun Pharma
13. Medicago Inc

Source: https://www.malaymail.com/news/malaysia/2020/12/09/the-13-covid-19-vaccines-in-the-final-stages-of-testing-to-be-used-in-malay/1930142

@Singapore88. Not seen yet.....
Maybe the forces of buyer comes from the retail investors + small sharks/bankers. If there is a big investor, they will hold 5% or more shareholding, therefore will be announced at BURSA as a substantial share holder.

Good day for today, Nexgram. Looking for better days next week.
Nexgram BOLEHH..

At least the JV news attract some attention and the incoming progress concerning it if any can spur more attraction and will give more investors confidence on the coy.

Just expecting a little improvement.

For medium term or long term investors, the 1st QR is coming at the end of this month...

@OKU_2020. Investors in cautious trade. Scare....

Attackkkkkkkkk.
Nexgram, THE NEW GEM IN HEALTHCARE BUSINESSES AND VACCINE PRODUCER AND VACCINE DISRIBUTOR TO BE...

Covid-19 VACCINE to manufacture and distribute (JV with Rafarma)
and,
Covid-19 Test Kits (agreement with MKN/MOH and MTC)
Covid-19 Test (via subsidiary in Indonesia)
Tracvirus with tracking vaccination is ready (contract with MOH)
Tracvirus SafeTravelPass (contract with MOH)
Medical gloves and PPE (gown) (contract with MAPU in Indonesia)
NexgramBottleVaccine (via subsidiary operation)

@frankietan.

frankietan The directors disposed milion of shares be careful .
-------------------------------------------
Is this "THE DIRECTOR' as you said?? Its the substantial share holder Ozura.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3112947

....... I think you better study who is Ozura, the one you said as the directors.

They are former creditor who being alloted ICPS as a settlement for their money owed by Nexgram. OZURA has no intention to be insider (long term investor) as their representative even not be elected as Board of Directors. If they want, they actually can join BOD because their shareholding is more than 10%.

The News About Nexgram JV:

https://www.msn.com/en-my/money/topstories/nexgram-inks-partnership-with-us-drug-manufacturer-to-supply-vaccines-in-indonesia/ar-BB1bOufC

https://www.klsescreener.com/v2/news/view/764923/nexgram-inks-partnership-with-us-drug-manufacturer-to-supply-vaccines-in-indonesia

Nexgram, THE NEW GEM IN HEALTHCARE BUSINESSES AND VACCINE PRODUCER AND VACCINE DISRIBUTOR TO BE...

Covid-19 VACCINE to manufacture and distribute (JV with Rafarma)
and,
Covid-19 Test Kits (agreement with MKN/MOH and MTC)
Covid-19 Test (via subsidiary in Indonesia)
Tracvirus with tracking vaccination is ready (contract with MOH)
Tracvirus SafeTravelPass (contract with MOH)
Medical gloves and PPE (gown) (contract with MAPU in Indonesia)
NexgramBottleVaccine (via subsidiary operation)

NEXGRAM HOLDINGS BERHAD ("NEXGRAM" OR "COMPANY")
MASTER STRATEGIC JOINT VENTURE AGREEMENT BETWEEN VACCINES LAB SDN BHD ("VACCINESLAB"), A WHOLLY OWNED SUBSIDIARY OF NEXGRAM WITH RAFARMA PHARMACEUTICALS INC. ("RAFARMA") ("PARTIES")

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3112948

@JK22 Only in Malaysia or it did happen in the rest of the world . Few cents company get into vaccine development and cheap to attract punter to frying up the stock
---------------------------------------------------------------
The answer #3:

THAT’S WHY THE VACCINELAB – RAFARMA JV CHOOSES INDONESIA AS A HUB FOR VACCINE PRODUCTION:

https://www.gmanetwork.com/news/news/world/765519/asean-should-lead-in-mass-production-of-covid-19-vaccine-says-adb-specialist/story/

https://www.hindustantimes.com/world-news/indonesia-has-strongest-capacity-for-vaccine-production-in-se-asia-china/story-kzO75A7SAUWmNRG46Yq1mJ.html

https://www.freemalaysiatoday.com/category/world/2020/10/11/china-backs-indonesia-to-become-vaccine-hub-of-southeast-asia/

@JK22 Only in Malaysia or it did happen in the rest of the world . Few cents company get into vaccine development and cheap to attract punter to frying up the stock
---------------------------------------------------------------
The answer #2:

------Vaccine Lab is included in the deal because via Nexgram Biomedic Sdn Bhd's subsidiary PT NDS Gobal Utama, Nexgram has been explored some Covid-19 businesses in Indonesia. With a number of contracts and as a distributor. Nexgram also has some contacts in Indonesia for sure. Therefore their joint venture firms are keen on Nexgram.

@JK22 Only in Malaysia or it did happen in the rest of the world . Few cents company get into vaccine development and cheap to attract punter to frying up the stock
---------------------------------------------------------------
The answer:

JOINT VENTURE BETWEEN VACCINE LAB (s/o NEXGRAM) WITH RAFARMA (US company)
(To open a vaccine facility in Indonesia to research, develop, conduct clinical trials and license for various in-demand vaccines including Covid-19)

R. & D. Biocogency Laboratories Inc (Cyprus)
(parent company of RAFARMA)
I
RAFARMA (US) ------------------------------- JV Vaccines Lab (sub of NEXGRAM)
I
PJSC Kraspharma(sub of RAFARMA) (Russia)


THE JOINT VENTURE AGREEMENT TERMS:

----- RAFARMA plan includes the investment of approximately USD1,000,000,000 (US Dollar One Billion) for the joint venture.

----- VACCINESLAB will provide government joint venture, partnership, regulation, licenses, and incentives for the project

----- The production capacity of the plant is designed for 500-600 million doses, covering the needs of the entire territory of Indonesia and the ASEAN countries

SEMUT YANG BANYAK NANTI BOLEH MENGALAHKAN GAJAH. He He

@SlayerZ. Hopefully

A POSSIBILITY:

Vaccine Lab + Rafarma Pharmaceuticals (US) + R. & D. Biocogency Laboratories Inc. (Cyprus) + subsidiary of Rafarma, PJSC Kraspharma (Russia) ———-> Russian or other source country Covid-19 vaccine ———> Indonesia and the ASEAN countries

@intel.. Tak ada yang mustahil dalam saham. GETS GLOBAL BERHAD dari 4.5 sen pada 23 Mac 2020 boleh mencecah setinggi RM3.97.
Lebih dekat lagi dengan Nexgram (ready to be vaccine counter) ialah saham HWGB (disebabkan covid-19 vaksin) dari harga terendah 6 sen mencapai harga tertinggi RM1.03.
Betullah kedua-duanya saham spekulatif....

Oww. Their NOSH ist it?

@kenie. I didn't get your point. Share consolidation? How

Russia belum mendapat pengiktirafan untuk penerimaan Sputnik V Vaccine dia di ASEAN kecuali di Filipina. Di Asia lainnya, India dan terima.
Melalui anak syarikat Nexgram, Vaccinelab mungkin diguna sebagai mediator untuk dapatkan peluang ini di Indonesia dan ASEAN
...... The Russian government had sent a letter to the Indonesia’s Health Ministry in September over the possibility of Sputnik V vaccine distribution, procurement and clinical trials. Preliminary results on the vaccine, which is currently in phase-three clinical trials, show its efficacy rate at 92 per cent, according to its developer, Gamaleya Research Institute.

Rafarma Merger Company Bebig Approved For Production And Sale Of Yttrium-90 For Treatment Of Inoperable Liver Cancer .... received an updated RUSSIAN registration certificate for the production and sale of nanostructured microspheres based on yttrium-90 https://finance.yahoo.com/news/rafarma-merger-company-bebig-approved-141500701.html CONNECTION RAFARMA WITH THE RUSSIAN ???????

He He. OKU_2020. The GHOST.

RATIONALE AND UTILISATION OF PROCEEDS
The proceeds from the Disposal will be used to repay bank overdraft and for working capital if
deemed fit.

Oh ya. Mana DRwarrant ni. Tak meriah tanpa dia. He He

Go Go Nexgram... Ini kalilahhhh...

KAG Group recording a loss of RM585,000

@jennyhee. it's not site but to add on telegram group discussion at (NXGRAM CLUB)

Still work for and wait for the announcement about vaccine deal at BURSA......

@OKU_2220. Thank you for your support. He He.